Scholarlink

Introduction <p>In clinical practice, intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection intervals for patients with neovascular age-related macular degeneration (nAMD) are based on disease activity, with active or recurrent disease requiring more frequent injections. Injection interval modification criteria differ from those used in clinical trials, thereby potentially affecting treatment outcomes. This analysis evaluated the potential impact of applying disease activity criteria from recent clinical trials (TENAYA/LUCERNE; HAWK/HARRIER; PULSAR) on the decision to extend injection intervals in real-world patients commenced on faricimab after the loading phase of treatment and at 12&#xa0;months.</p> Methods <p>Data were analysed from 105 treatment-naïve patients with nAMD who received anti-VEGF injections at Moorfields Eye Hospital. Disease activity criteria from TENAYA/LUCERNE, HAWK/HARRIER and PULSAR clinical trials were applied to determine the hypothetical impact on the decision to modify injection intervals at week&#xa0;12 (fourth injection) and 12-month real-world clinic visits.</p> Results <p>At 12&#xa0;weeks,&#xa0;79% of patients had injection intervals extended in clinical practice compared to 80% when applying hypothetical TENAYA/LUCERNE disease activity criteria; 77% using HAWK/HARRIER and 96% using PULSAR. There was agreement between clinical practice and all clinical trials in 60% of eyes, and no agreement in 13%. At 12&#xa0;months, fewer patients were inactive, with 55% of eyes quiescent in clinical practice, 58% when applying TENAYA/LUCERNE criteria and 67% using HAWK/HARRIER. Application of PULSAR disease activity criteria showed 96% of patients were classed as inactive. 34% of eyes showed agreement in disease activity status between clinical practice and all clinical trials at 12&#xa0;months, with no agreement in 20%.</p> Conclusions <p>Applying disease activity criteria from clinical trials to clinical practice can have a significant impact on hypothetical anti-VEGF injection intervals. Consideration should be paid to which criteria are used in real-world practice to help achieve treatment burden reductions and optimal treatment outcomes seen in clinical trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Impact of Disease Activity Criteria on Extending Injection Intervals in Real-World Patients with Neovascular Age-Related Macular Degeneration

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月27日

查看全文
  • Bhairavi Bhatia,
  • Sing Yue Sim,
  • Evangelia Chalkiadaki,
  • Georgios Koutsocheras,
  • Luke Nicholson,
  • Senthil Selvam,
  • Sobha Sivaprasad,
  • Bishwanath Pal,
  • Josef Huemer,
  • Pearse A. Keane,
  • Robin Hamilton,
  • Praveen J. Patel,
  • Abison Logeswaran,
  • Adnan Tufail,
  • Avinash Gurbaxani,
  • Bishwanath Pal,
  • Catherine Egan,
  • David Bessant,
  • Dhanes Thomas,
  • Heng Ling,
  • Josef Huemer,
  • Khadijah Basheer,
  • Konstantinos Balaskas,
  • Konstantinos Bouras,
  • Luke Nicholson,
  • Lyndon Da Cruz,
  • Mythili Natkunarajah,
  • Narciss Okhravi,
  • Niaz Islam,
  • Parul Desai,
  • Pearse A. Keane,
  • Peter Addison,
  • Praveen J. Patel,
  • Ranjan Rajendram,
  • Robin Hamilton,
  • Senthil Selvam,
  • Simona Esposti,
  • Sobha Sivaprasad,
  • Tjebo Heeren,
  • Waheeda Rahman,
  • Yasir Khan,
  • Zoe Ockrim,
  • Zubin Saihan

摘要

Introduction

In clinical practice, intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection intervals for patients with neovascular age-related macular degeneration (nAMD) are based on disease activity, with active or recurrent disease requiring more frequent injections. Injection interval modification criteria differ from those used in clinical trials, thereby potentially affecting treatment outcomes. This analysis evaluated the potential impact of applying disease activity criteria from recent clinical trials (TENAYA/LUCERNE; HAWK/HARRIER; PULSAR) on the decision to extend injection intervals in real-world patients commenced on faricimab after the loading phase of treatment and at 12 months.

Methods

Data were analysed from 105 treatment-naïve patients with nAMD who received anti-VEGF injections at Moorfields Eye Hospital. Disease activity criteria from TENAYA/LUCERNE, HAWK/HARRIER and PULSAR clinical trials were applied to determine the hypothetical impact on the decision to modify injection intervals at week 12 (fourth injection) and 12-month real-world clinic visits.

Results

At 12 weeks, 79% of patients had injection intervals extended in clinical practice compared to 80% when applying hypothetical TENAYA/LUCERNE disease activity criteria; 77% using HAWK/HARRIER and 96% using PULSAR. There was agreement between clinical practice and all clinical trials in 60% of eyes, and no agreement in 13%. At 12 months, fewer patients were inactive, with 55% of eyes quiescent in clinical practice, 58% when applying TENAYA/LUCERNE criteria and 67% using HAWK/HARRIER. Application of PULSAR disease activity criteria showed 96% of patients were classed as inactive. 34% of eyes showed agreement in disease activity status between clinical practice and all clinical trials at 12 months, with no agreement in 20%.

Conclusions

Applying disease activity criteria from clinical trials to clinical practice can have a significant impact on hypothetical anti-VEGF injection intervals. Consideration should be paid to which criteria are used in real-world practice to help achieve treatment burden reductions and optimal treatment outcomes seen in clinical trials.